12 Month Price Forecast For CRMD
Distance to CRMD Price Forecasts
CRMD Price Momentum
๐ค Considering CorMedix (CRMD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 1:00 PM UTC
CRMD Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, CRMD has a bullish consensus with a median price target of $17.00 (ranging from $12.00 to $19.00). Currently trading at $10.48, the median forecast implies a 62.2% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Butler at JMP Securities, projecting a 81.3% upside. Conversely, the most conservative target is provided by Gregory Renza at RBC Capital, suggesting a 14.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRMD Analyst Consensus
CRMD Price Target Range
Latest CRMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRMD.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $15.00 |
Dec 19, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $12.00 |
Oct 31, 2024 | Needham | Serge Belanger | Buy | Maintains | $18.00 |
Oct 22, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $17.00 |
Aug 26, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $13.00 |
Aug 15, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
Aug 15, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $9.00 |
Jul 25, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $12.00 |
Jun 19, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
May 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
Apr 9, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
Apr 9, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $19.00 |
Mar 13, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $9.00 |
Mar 12, 2024 | Needham | Serge Belanger | Buy | Maintains | $10.00 |
Jan 31, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $14.00 |
Nov 15, 2023 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $19.00 |
Nov 15, 2023 | Needham | Serge Belanger | Buy | Maintains | $10.00 |
Nov 15, 2023 | Truist Securities | Joon Lee | Buy | Reiterates | $18.00 |
Nov 15, 2023 | RBC Capital | Gregory Renza | Outperform | Maintains | $10.00 |
Stocks Similar to CorMedix Inc
The following stocks are similar to CorMedix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CorMedix Inc (CRMD) Financial Data
CorMedix Inc has a market capitalization of $635.90M with a P/E ratio of -11.5x. The company generates $12.26M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +1,321.1% quarter-over-quarter, while maintaining an operating margin of -28.7% and return on equity of -65.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

CorMedix Inc (CRMD) Company Overview
About CorMedix Inc
Develops products for infectious disease treatment.
CorMedix Inc. generates revenue through the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. Their primary product candidate, DefenCath, is designed to minimize catheter-related bloodstream infections, targeting a significant healthcare market, particularly among patients with kidney failure.
Founded in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix was previously known as Picton Holding Company, Inc. The company has a focused strategy on addressing critical health issues in the United States, which may appeal to investors looking for opportunities in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
82
CEO
Mr. Joseph Todisco MBA
Country
United States
IPO Year
2010
Website
www.cormedix.comCorMedix Inc (CRMD) Latest News & Analysis
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
1 month agoCorMedix Inc. reports Q4 2024 unaudited net revenue of approximately $31 million and FY 2024 net revenue of about $43 million, with Q4 adjusted EBITDA expected to exceed $12 million.
CorMedix's preliminary revenue figures indicate strong performance, with Q4 revenue of $31 million and anticipated adjusted EBITDA over $12 million, signaling potential growth and financial health.
CRMD reported $31 million in preliminary Q4 sales from its sole product, exceeding its prior guidance of achieving break-even by 2024.
CRMD's Q4 sales of $31 million indicate strong demand and growth potential, exceeding guidance, which could enhance investor confidence and drive stock performance.
CorMedix (CRMD) and ResMed (RMD) have exhibited performance metrics that can be compared to their respective sectors year-to-date.
Performance comparisons indicate how well CorMedix and ResMed are faring against their peers, influencing investor sentiment and potential investment decisions in the healthcare sector.
CorMedix Inc. (Nasdaq: CRMD) will be added to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, prior to market open.
CorMedix's inclusion in the Nasdaq Biotechnology Index can enhance its visibility, attract institutional investors, and potentially boost its stock price due to increased demand.
CorMedix Inc. (Nasdaq: CRMD) notes new CMS policy changes enhancing access to innovative therapies for Medicare patients with End Stage Renal Disease and on dialysis.
Policy changes by CMS could enhance market opportunities for CorMedix, potentially increasing revenue from their therapeutic products for hemodialysis patients.
CorMedix (CRMD) has been upgraded to Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, potentially boosting the stock price.
CorMedix's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price up in the near term.
Frequently Asked Questions About CRMD Stock
What is CorMedix Inc's (CRMD) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, CorMedix Inc (CRMD) has a median price target of $17.00. The highest price target is $19.00 and the lowest is $12.00.
Is CRMD stock a good investment in 2025?
According to current analyst ratings, CRMD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRMD stock?
Wall Street analysts predict CRMD stock could reach $17.00 in the next 12 months. This represents a 62.2% increase from the current price of $10.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CorMedix Inc's business model?
CorMedix Inc. generates revenue through the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. Their primary product candidate, DefenCath, is designed to minimize catheter-related bloodstream infections, targeting a significant healthcare market, particularly among patients with kidney failure.
What is the highest forecasted price for CRMD CorMedix Inc?
The highest price target for CRMD is $19.00 from Jason Butler at JMP Securities, which represents a 81.3% increase from the current price of $10.48.
What is the lowest forecasted price for CRMD CorMedix Inc?
The lowest price target for CRMD is $12.00 from Gregory Renza at RBC Capital, which represents a 14.5% increase from the current price of $10.48.
What is the overall CRMD consensus from analysts for CorMedix Inc?
The overall analyst consensus for CRMD is bullish. Out of 11 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are CRMD stock price projections?
Stock price projections, including those for CorMedix Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.